Evidence map›Paper›PMID 40124340›Full record

ArticleMaterials today. Bio2025

PD-L1 siRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion.

Jingsheng Zhou, Yuanyuan Li, Xianghe Jiang, Zhongyuan Xin, Wenshang Liu, Xinyi Zhang, Yonghua Zhai, Zhuanzhuan Zhang, Te Shi, Minghao Xue and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jingsheng ZhouChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Yuanyuan LiChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Xianghe JiangChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Zhongyuan XinChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Wenshang LiuDepartment of Dermatology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China.
Xinyi ZhangInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Yonghua ZhaiDepartment of Cardiovascular Medicine, Department of Hypertension, Ruijin Hospital and State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, China.
Zhuanzhuan ZhangInstitute of Translational Medicine, Shanghai University, Shanghai, 200444, China.
Te ShiDepartment of Gastroenterology, Chinese People's Liberation Army Naval Medical Center, Shanghai, 200052, China.
Minghao XueChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Mengya ZhangChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Yan WuCollege of Life Science, Mudanjiang Medical University, Mudanjiang, 157011, China.
Yanhui ChuCollege of Life Science, Mudanjiang Medical University, Mudanjiang, 157011, China.
Shimin WangDepartment of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200000, China.
Xin JinDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Weiping ZhuDepartment of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, 200032, China.
Jie GaoChanghai Clinical Research Unit, The First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Engaging antigen-presenting cells and T lymphocytes is essential for invigorating the immune system's response to cancer. Nonetheless, challenges such as the low immunogenicity of tumor antigens, the genetic heterogeneity of tumor cells, and the elevated expression of immune checkpoint molecules frequently result in resistance to immunotherapy or enable immune evasion by tumors. To overcome this resistance, we developed a therapeutic tumor vaccine employing cationic liposomes to encapsulate MC38 total RNA alongside PD-L1 siRNA (siPD-L1). The encapsulated total RNA, enriched with tumor mRNA, effectively transduces dendritic cells (DCs), thereby enhancing antigen presentation. The incorporation of siPD-L1 specifically targets and diminishes PD-L1 expression on both DCs and tumor cells, synergistically amplifying the cytotoxic capabilities of CD8

Indexed as

AutophagyCationic liposomesmRNAPD-L1Tumor vaccine

Identifiers

PMID40124340
PMCPMC11926701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.